Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8616146 | 0.83 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25939272 | 0.80 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL8616578 | 0.79 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8618830 | 0.79 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL27384069 | 0.79 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL20852991 | 0.79 | RIPK1 (0.34) | RIPK1 | |
| SCHEMBL28680153 | 0.79 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL20683535 | 0.78 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23584228 | 0.77 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL23425906 | 0.75 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988606-A1 | POLYROTAXANE COMPRISING LONG-CHAIN ALKYL GROUP IN CYCLIC MOLECULE, COMPOSITION COMPRISING SAID POLYROTAXANE, AND METHOD FOR PRODUCING SAID POLYROTAXANE | ASM Inc. (JP) | 2022-04-27 | — | — | EP | disclosed |
| US-8871304-B2 | (Amide amino alkane) metal compound, method of manufacturing metal-containing thin film using said metal compound | UBE INDUSTRIES, LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20130273250-A1 | (AMIDE AMINO ALKANE) METAL COMPOUND, METHOD OF MANUFACTURING METAL-CONTAINING THIN FILM USING SAID METAL COMPOUND | UBE INDUSTRIES, LTD (JP) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273250-A1 | (AMIDE AMINO ALKANE) METAL COMPOUND, METHOD OF MANUFACTURING METAL-CONTAINING THIN FILM USING SAID METAL COMPOUND | GNMT, SLC43A1, BET1 | CHRNB2 2303/4885CHRNA4 1734/4885CHRNB4 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.